Skip to main content
Fig. 8 | BMC Bioinformatics

Fig. 8

From: LincRNA ZNF529-AS1 inhibits hepatocellular carcinoma via FBXO31 and predicts the prognosis of hepatocellular carcinoma patients

Fig. 8

Evaluation of ZNF529-AS1 for predicting treatment response in HCC patients. A Difference analysis between ZNF529-AS1 and clinical response to HCC immunotherapy; B correlation between the high expression group and low expression group in the enrichment score of the immunotherapy prediction path; C correlation between ZNF529-AS1 and the enrichment score of the immunotherapy prediction pathways; D correlations between ZNF529-AS1 and various steps of the cancer-immunity cycle

Back to article page

BMC Bioinformatics

ISSN: 1471-2105

Contact us